Search hospitals > North Carolina > Huntersville
Novant Health Presbyterian Medical Center Huntersville
Claim this profileHuntersville, North Carolina 28078
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
Conducts research for Serous Cystadenocarcinoma
15 reported clinical trials
6 medical researchers
Summary
Novant Health Presbyterian Medical Center Huntersville is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Serous Cystadenocarcinoma and other specialties. Novant Health Presbyterian Medical Center Huntersville is involved with conducting 15 clinical trials across 69 conditions. There are 6 research doctors associated with this hospital, such as Alan Skarbnik, MD, Nasfat Shehadeh, M.D., Obiageli U. Ogbata, and Kimberly S. Strickland.Area of expertise
1Cancer
Stage II
Stage I
Stage IV
2Breast Cancer
HER2 positive
ER negative
HER2 negative
Top PIs
Alan Skarbnik, MDNovant Health Presbyterian Medical Center5 years of reported clinical research
Studies Lymphoma
Studies Chronic B-Cell Leukemia
7 reported clinical trials
15 drugs studied
Nasfat Shehadeh, M.D.Novant Health Presbyterian Medical Center9 years of reported clinical research
Studies Breast Cancer
Studies Carcinoma
5 reported clinical trials
11 drugs studied
Obiageli U. OgbataNovant Health Presbyterian Medical Center3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
4 reported clinical trials
8 drugs studied
Kimberly S. StricklandNovant Health Presbyterian Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
5 reported clinical trials
17 drugs studied
Clinical Trials running at Novant Health Presbyterian Medical Center Huntersville
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Mantle Cell Lymphoma
ALK Gene Rearrangement
Recurrence
Lymphoma
Neoplasm
B-Cell Lymphoma
Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novant Health Presbyterian Medical Center Huntersville?
Novant Health Presbyterian Medical Center Huntersville is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Serous Cystadenocarcinoma and other specialties. Novant Health Presbyterian Medical Center Huntersville is involved with conducting 15 clinical trials across 69 conditions. There are 6 research doctors associated with this hospital, such as Alan Skarbnik, MD, Nasfat Shehadeh, M.D., Obiageli U. Ogbata, and Kimberly S. Strickland.